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Abstract
Objective Opioids are recommended by the World Health
Organization for moderate to severe cancer pain. Oxy-
codone is one of the most commonly used opioids and is
metabolized in the liver by CYP3A4 and CYP2D6
enzymes. The aim of this cross-sectional study was to
assess the relationship between oxycodone pharmacokinet-
ics, pharmacodynamics and the CYP2D6 genotypes “poor
metaboliser” (PM), “extensive metaboliser” (EM) and
“ultra-rapid metaboliser” (URM) in a cohort of patients
with cancer pain.
Methods The patients were genotyped for the most common
CYP2D6 variants and serum concentrations of oxycodone
and metabolites were determined. Painwas assessed using the
Brief Pain Inventory (BPI). The EORTC QLQ-C30 was used
to assess the symptoms of tiredness and nausea. Cognitive
function was assessed by the Mini Mental State (MMS)
examination. Associations were examined by analyses of
variance (ANOVA) and covariance (ANCOVA), or ordinal
logistic regressions with and without covariates.
Results The sample consisted of 27 PM, 413 EM (including
heterozygotes) and 10 URM. PM had lower oxymorphone
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DOI 10.1007/s00228-011-1093-5and noroxymorphone serum concentrations and oxymor-
phone to oxycodone ratios than EM and URM. No
differences between PM, EM and URM in pain intensity,
nausea, tiredness or cognitive function was found.
Conclusion CYP2D6 genotypes caused expected differences
in pharmacokinetics, but they had no pharmacodynamic
consequence. CYP2D6 genotypes did not influence pain
control, the adverse symptoms nausea and sedation or the
risk for cognitive failure in this study of patients treated with
oxycodone for cancer pain.
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Introduction
The World Health Organisation (WHO) recommends
opioids for the relief of moderate to severe cancer pain
[1]. Oxycodone is one of most commonly used opioids [2–
4]. Oxycodone is metabolised in the liver mainly by
CYP3A4 to noroxycodone, but also by CYP2D6 to
oxymorphone, and via 6-keto reduction to α-a n dβ-
oxycodol. Noroxycodone and oxymorphone are further
metabolised to noroxymorphone by CYP2D6 and
CYP3A4 respectively [5]. CYP3A4 and CYP2D6 belong
to the cytochrome P450 system, the principal enzyme
system for phase I metabolism. This system is present in
virtually all tissues, but is most abundant in the liver and
in the small intestine [6]. The CYP3A4 gene has many
known polymorphisms, but no clinically important differ-
ences between genotypes have been observed [7, 8].
CYP2D6 has several known polymorphisms that influence
drug metabolism. Inactivating polymorphisms cause gene
mutations and deletion(s) that result in a non-functional
enzyme, whereas gene duplication(s) cause over-expression
of active enzyme. Individuals with two non-functional alleles
of CYP2D6 are genotyped “poor metaboliser” (PM, 5–10%
of Caucasians), whilst individuals with one decreased
functional allele and one non-functional allele or two
decreased functional alleles are “intermediate metabo-
liser” (IMs, 10–15% of Caucasians). Persons with two
wild-type alleles (CYP2D6*1), or one functional and one
non-functional allele, are referred to as “extensive metab-
oliser” (EM, 72–84% of Caucasians). Individuals with
more than duplicates of the CYP2D6 gene are “ultra-rapid
metaboliser” (URM, 1–3% of Caucasians) [9, 10].
Because poor metabolisers are unable to metabolise
CYP2D6 substrates, a drug administered at normal dose
m a yl e a dt oh i g ho rt o x i cl e v e l so ft h ed r u g[ 11, 12]. On
the other hand, an ultra-rapid metaboliser may experience
reduced or no effect when given a drug that is a CYP2D6
substrate, or they may experience adverse drug reactions
[13, 14]. The CYP2D6 genotype may therefore be of
clinical importance for drugs that are metabolised by
CYP2D6 enzymes.
The effect of the CYP2D6 genotype on the pharmaco-
dynamics of oxycodone in a clinical setting of patients with
cancer pain receiving chronic opioid administration has not
previously been studied. This led us to the following
research questions:
1. Do the CYP2D6 genotypes predict oxycodone and
metabolite serum concentrations in patients treated for
cancer pain?
2. Is the CYP2D6 genotype associated with pain intensity,
or the intensity of nausea, tiredness or cognitive
function in cancer patients receiving oxycodone?
Materials and methods
Ethics
This multicentre study was performed according to the
guidelines of the Helsinki Declaration and was approved by
the relevant Research Ethics Committee of each study
centre. Before entering the study, all participating patients
gave their informed written consent.
Patients
Thepatientswereincludedfrom2004to2008inamulticentre
cross-sectional study, the European Pharmacogenetic Opioid
Study(EPOS)[15], designed to explore hypotheses related to
the pharmacogenetics of opioid analgesics. A convenience
sample of 2,294 patients from 17 centres in 11 European
countries were included in EPOS, with 461 patients (98%
Caucasians) treated with oxycodone. Eleven patients were
excluded; 8 because of a lack of DNA samples, and 3
because of incomplete CYP2D6 genotype analyses. Thus,
450 were included in the final analyses. Patients included in
the present analysis were aged 18 years or more, had a
verified malignant disease, and received scheduled oral,
subcutaneous, or intravenous oxycodone treatment with a
duration of treatment no less than 3 days. Patients who were
not capable of speaking the language used at the study centre
were excluded.
Assessments
At the time of inclusion the following information was
collected from each patient: age, gender, weight, height,
ethnicity, medications and dosages, the time interval
between last opioid administration and blood sampling,
time since opioid treatment started, breakthrough pain,
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was assessed using the item “Pain on the average” from the
Brief Pain Inventory (BPI), which has a numeric rating
scale (NRS) from 0 (“No pain”)t o1 0( “Pain as bad as you
can imagine”)[ 16]. The Mini Mental State (MMS)
examination was used to assess cognitive function [17].
Cognitive failure was defined as having a total MMS of 23
or less [18, 19]. Functional status was assessed by the
Karnofsky performance status [20]. The Karnofsky perfor-
mance status has a linear scoring from 0 to 100%, with
higher scores meaning better function. The European
Organisation for Research and Treatment of Cancer’s
health-related quality-of-life (QoL) questionnaire (EORTC
QLQ-C30) version 3.0 was used to assess the patient’s self-
reported QoL for the symptoms tiredness, nausea, consti-
pation and depression. Tiredness was assessed using the
item “Were you tired?” and depression was assessed using
the item “Did you feel depressed?” with alternatives “not at
all”, “a little”, “quite a bit” and “very much” for both items.
Nausea and constipation were assessed using the symptom
scale for nausea and vomiting, and constipation respective-
ly. Scoring of the symptom scales were done by a linear
transformation to a 0 to 100 scale. A score of 0–24 on these
symptom scales corresponds to “not at all”,2 5 –49
corresponds to “a little”,5 0 –74 to “quite a bit” and 75–
100 to “very much” [21, 22]. Standard analytical methods
applied at each centre were used for haemoglobin,
creatinine and albumin measurements. Body mass index
(BMI) was calculated using the international system of
units, BMI=weight (kg)/height
2 (m
2). Renal function was
expressed as calculated glomerular filtration rate (GFR)/
1.73 m
2 body surface [23, 24].
Blood samples were obtained shortly prior to drug
administration of the patients’ scheduled oral opioid
medication (trough value). For practical reasons blood
samples from out-patients (n=68) were taken at the time
of examination. Blood samples for opioid analyses in serum
were collected in tubes with no additives and left at ambient
temperature for 30–60 min before centrifugation at 2,500×g
(approximately 3,000 rpm) for 10 min. Serum was then
aliquoted and stored at −80°C prior to analysis.
Serum concentration analyses
Details on handling of blood samples, analytical technique
and instrumentation for serum concentration analyses of
oxycodone, and the metabolites oxymorphone, noroxyco-
done and noroxymorphone have been described previously
[25]. Pharmacological analyses were carried out using a
LC-MS/MS system. Correlation coefficients were r>0.998
for all standard curves. Coefficients of variation (intra- and
inter-day) for each analyte were 16.5 and 8.3% for
oxycodone, 10.8 and 6.7% for noroxycodone, 10.0 and
7.5% for oxymorphone and 14.8 and 7.7% for noroxymor-
phone. The limits of quantification were oxycodone
0.32 nM (0.1 ng/ml), oxymorphone 0.07 nM (0.02 ng/ml),
noroxycodone and noroxymorphone 0.17 nM (0.05 ng/ml).
Genetic analyses
Blood samples for genetic analysis were collected at the
time of inclusion in vacutainers containing EDTA (K2-
EDTA, 5.4 mg/3 ml blood). The blood was aliquoted into
cryotubes and frozen (−80°C) until isolation of DNA. DNA
was isolated by a modified salting-out precipitation method
for purification (Gentra Puregene Blood Kit, Gentra
Systems, Mineapolis, MN, USA). Purified DNA was stored
at −20°C prior to analysis.
CYP2D6 genotyping
CYP2D6*2x2 (duplication) was detected according to the
method of Lovlie et al. [26], with some modifications. PCR
was performed using the Gene Amp XL PCR kit (Roche/
Applied Biosystems, Foster City, NJ, USA) in 50 μl
reaction volumes with a hot start. The lower reaction mix
layer contained 4.5 μld H 2O, 6 μl 3.3 XL Buffer II,
2.5 μl Mg(OAc)2 (25 mM), 4 μl dNTP Mix (10 mM), and
1.5 μl of each primer (10 mM). To separate the lower and
upper reaction mix layer, wax was melted on top of the
lower reaction mix (80°C, 3–4 min), and then cooled to
room temperature. Then the upper reaction mix containing
18.5 μl dH2O, 9 μl 3.3 XL Buffer II, 1 μlr Tth DNA
polymerase (2 U/μl) and 2.5 μl genomic DNA (5–10 ng/μl)
was added.
Long PCR was carried out on a Techne TC-512 (Barlo-
world Scientific, Stone, Staffordshire, UK) with the following
conditions: an initial denaturing step of 95°C for 1 min,
followed by 35 cycles of 94°C for 1 min, 65°C for 30 s and
68°C for 2 min (+18 s increase for every new cycle), and a
final elongation step of 72°C for 10 min.
The resulting long PCR products were separated and
detected by electrophoresis (30 mA, 40 min) with 1.2%
agarose gels containing ethidium bromide and tris-acetate
buffer (Invitrogen, Carlsbad, CA, USA).
Detection of CYP2D6*5 (deletion) was done in
accordance with the method of Steen et al. [27]a n d
Hersberger et al. [28], with some modifications. PCR was
performed using the Gene Amp XL PCR kit (Roche/
Applied Biosystems, Foster City, NJ, USA) in 50 μl
reaction volumes with a hot start. To separate lower and
upper reaction mix, heated wax was used (as described for
detection of CYP2D6*2x2). The lower reaction mix
contained 1.95 μl dH2O, 6 μl3 . 3X LB u f f e rI I ,
2.05 μl Mg(OAc)2 (25 mM), 4 μld N T PM i x( 1 0m M )
and 1.5 μlo fe a c hp r i m e r( 1 0m M ;T a b l e1). The upper
Eur J Clin Pharmacol (2012) 68:55–64 57reaction mix was as described for the detection of
CYP2D6*2x2. The PCR conditions, and identification of
the amplification products, were done in the same way as
described for CYP2D6*2x2.
Long distance and multiplex PCR techniques were
combined for the simultaneous detection of the five allele
groups, *3, *4, *6, *7 and *8 in genomic DNA. Patients
who lacked these mutations were categorised as having the
CYP2D6*1 (functional) allele. With some modifications,
these reactions were done in accordance with the method of
Stüven et al. [29].
First CYP2D6 was specifically amplified as a 4.7-kb
fragment by a pre-multiplex long PCR with a hot start. To
separate lower and upper reaction mix, heated wax was
used (as described for the detection of CYP2D6*2×2).
PCR was performed using the Gene Amp XL PCR kit
(Roche/Applied Biosystems, Foster City, NJ, USA) in 50-μl
reaction volumes. The lower reaction mix contained 4.5 μl
dH2O,6μl3.3XL Buffer II, 2.5 μlM g ( O A c ) 2( 2 5m M ) ,
4 μld N T PM i x( 1 0m M )a n d1 . 5μl of each primer
(10 mM). The upper reaction mix was as described for the
detection of CYP2D6*2×2. The pre-multiplex long PCR
conditions, and identificationof the 4.7-kb PCR product,
were done in the same way as for CYP2D6*2x2.
The CYP2D6-specific 4.7-kb pre-amplification product
was then used as a template for two separate PCR reactions
with primers complementary to either the specific inactivat-
ing variant or the corresponding normal (wild-type) allele at
each potential mutation site. Reactions (25 μl) contained
0.8 μl dH2O, 2.5 μl 10x PCR Gold Buffer, 1.5 μl MgCl2
(25 mM), 0.7 μl dNTP Mix (10 mM), 0.5 μl AmpliTaq
Gold Polymerase (5 U/μl; all reagents from Applied
Biosystems), 0.2 μl of the CYP2D6-specific 4.7 kb pre-
amplification product and 3.76 μl of each of the following
primers in the normal reaction; M (1.06 μM), A1
(0.10 μM), B1 (0.11 μM), E3 (0.12 μM) and T1
(0.64 μM), and for the mutation reaction 3.13 μl of each
primer M (1.06 μM), A2 (0.10 μM), B2 (1.06 μM), E4
(0.10 μM), G2 (0.50 μM) and T2 (0.05 μM) was used.
Polymer chain reaction was carried out on a Techne TC-
512 (Barloworld Scientific) with the following conditions:
an initial denaturing step of 95°C for 5 min, followed by 14
cycles of 94°C for 1 min, 55°C for 30 s and 72°C for 2 min
20 s, and a final elongation step of 72°C for 5 min.
The resulting long PCR products were separated and
detected by electrophoresis (25 mA, 45 min) with 4.0%
agarose gels containing ethidium bromide and tris-acetate
buffer (Invitrogen, Carlsbad, CA, USA).
The patients were divided into three genotype groups:
PM: Patients with two non-functional alleles.
EM: Those categorised as having two of the wild-type
allele (CYP2D6*1 homozygote EM), and in addition
patients with one functional allele and one non-
functional allele or an allele with decreased function
(heterozygote EM).
URM: Patients with more than duplicates of the
CYP2D6 gene.
Statistics
Descriptive group data are given as median (minimum–
maximum) values. Comparisons between the genetic
groups for the continuous descriptive data were explored
with analyses of variance (one-way ANOVA). For the
descriptive categorical data the comparisons were explored
with logistic regression analyses. Median oxycodone and
metabolite serum concentrations were calculated from all
450 patients independent of the time since the last dose to
blood sample and opioid used as rescue medication.
Comparisons between the three genetic groups for the
continuous variables (serum concentrations of oxycodone,
noroxycodone, oxymorphone and noroxymorphone, and
the oxymorphone/oxycodone ratio, pain intensity and
cognitive function) were explored with analysis of variance
(one-way ANOVA) and tested for homogeneity. For the
variables where the overall F-test showed to be significant
(p≤0.05), the Games–Howell procedure [30] was chosen
for the post-hoc tests. The analyses were then repeated with
non-genetic covariates previously found to influence the
outcomes [25]. For serum concentrations of oxycodone and
the metabolites and the ratio oxymorphone/oxycodone
these were: oxycodone total daily dose, use of CYP3A4
inhibitors or inducers, sex, time since last oxycodone dose,
Table 1 Distribution of the CYP2D6 alleles and the corresponding
genotype for the genetic groups: extensive metabolisers (EM), poor
metabolisers (PM) and ultra-rapid metabolisers (URM) for the 450
patients with cancer pain
Genotype n Percentage of total
population
EM homozygote 413 91.7
*1/*1 (wild-type) heterozygote 243 54.0
*1/*5 (deletion) 23 5.1
*1/*3 12 2.7
*1/*4 124 27.6
*1/*6 11 2.4
PM 27 6.0
*3/*4 2 0.4
*4/*4 22 4.9
*4/*6 3 0.7
URM 10 2.2
*2/*2 (duplication) 10 2.2
None of the patients had the *1/*7 and *1/*8 allele variants
58 Eur J Clin Pharmacol (2012) 68:55–64the number of medications other than opioids used in the
last 24 h, albumin serum concentrations, use of steroids,
BMI and glomerular filtration rate. Covariates in the
analyses of pain intensity were oxymorphone serum
concentrations, mixed pain, breakthrough pain, paracetamol
medication, depression status, constipation status, female
reproductive organ cancer and use of fluconazole. Cova-
riates in the analyses of cognitive function were: age,
Karnofsky and depression status, use of CYP2D6 inhib-
itors, steroid medication and breast cancer. Post-hoc
ANCOVA comparisons between genetic groups were
performed with Sidak [31] corrected p values.
Comparisons between the three genetic groups and
categorical data (nausea and tiredness) were explored by
ordinal logistic regression without covariates. The analyses
were then repeated with inclusion of non-genetic covariates
previously known to influence the outcomes [25]. For
nausea these covariates were sex, depression status, prostate
cancer or diagnosis of unknown origin, constipation status,
use of anti-emetics and steroids. In the analysis of tiredness
depression status, breast cancer, Karnofsky status and
albumin status were included covariates. The statistical
software SPSS for Windows v. 16.0 was used for all
statistical analyses.
Results
Patients
We analysed 450 patients receiving oxycodone for cancer
pain. Six percent (n=27) were genotyped as poor metab-
olisers (PM), about 92% (n=413) were extensive metabo-
lisers (EM), while about 2% (n=10) were genotyped as
ultra-rapid metabolisers (URM). The distribution of the
CYP2D6 genotypes is shown in Table 1. None of the
patients had the *7 and *8 allelic variants. The allelic
distributions followed the Hardy—Weinberg equation.
Descriptive data are shown in Table 2 and given as median
(minimum to maximum) if not stated otherwise. Most of the
demographic data were similar in the three genetic groups.
However, the median Karnofsky performance status was 70%
PM (n=27) EM (n=413) URM (n=10)
Gender: female/male (%) 16/11 (59/41) 180/233 (44/56) 2/8 (20/80)
Age (years)
a 62 (19–84) 62 (18–91) 63 (44–81)
Karnofsky performance status (%)
a* 50 (20–90) 70 (20–90) 55 (30–70)
Body mass index (kg/m
2)
a 23 (14–30) 23 (14–41) 23 (19–28)
Glomerular filtration rate (ml/min/1.73 m
2)
a 77 (27–239) 96 (24–261) 115 (42–194)
Albumin serum (g/L)
a 31 (10–49) 33 (11–91) 29 (22–36)
Time since diagnosis (months)
a 31 (0–155) 16 (0–286) 31 (0–79)
Time since opioid treatment started (months)
a 1( 0 –42) 1 (0–97) 2 (0–21)
Time since last dose (hours)
a 11 (1–13) 10 (0.1–17) 11 (0.8–12)
Number of medication ex. opioids
a 7( 3 –14) 6 (0–17) 9 (3–12)
CYP2D6 inhibitor medication
b 23 5 1
CYP3A4 inhibitor medication
b 22 1 1
CYP3A4 inducer medication
b*0 22
Breakthrough pain: yes/no (%) 18 / 9 (67/33) 256/156 (62/38) 8/2 (80/20)
Cancer diagnosis:
Gastrointestinal (inclusive pancreas, liver)
c 28 7 3
Lung (inclusive mesothelioma)
c 67 0 1
Prostate
c 47 0 3
Other urological
c 02 6 1
Breast
c* 8 56 0
Female reproductive organs
c 13 3 0
Haematological
c 12 9 0
Head and neck
c 11 0 0
Sarcoma
c 18 1
Skin
c 18 0
Other
c 22 3 1
Unknown origin
c 11 2 0
More than one diagnosis
c 11 7 0
Table 2 Patient demographics
for poor metabolisers (PM),
extensive metabolisers (EM) and
ultra-rapid metabolisers (URM )
*p<0.05
aMedian (minimum to maximum)
bNumber of users
cNumber
Eur J Clin Pharmacol (2012) 68:55–64 59for EM and 50 and 55% for PM and URM respectively (p=
0.0004). Also, use of CYP3A4 inducer medications was
statistically significantly different in PM (n=0) compared with
the other to genetic groups (n=2 for both groups; p<0.05).
Pharmacokinetics
Oxycodone total daily dose and serum concentrations for
the three genetic groups are shown in Figs. 1 and 2.
Median oxycodone total daily dose were 80, 75 and
70 mg/24 h for the PM, EM, and URM respectively.
Median serum concentrations of oxycodone were 110, 107
and 74 nM, noroxycodone 196, 101 and 118 nM, oxy-
morphone 0.2, 1.6 and 2.3 nM, and noroxymorphone 2.5,
18.0 and 34.0 nM for the PM, EM and URM respectively.
There were no statistical differences among the three genetic
groups with respect to oxycodone (F(2, 444)=0.01, p=0.99)
and noroxycodone serum concentrations (F(2, 444)=2.35,
p=0.10). There was a significant difference in serum
concentrations of oxymorphone (F(2,444)=30.79, p<0.000)
and noroxymorphone (F(2,444)=43.43, p<0.000) among the
three genetic groups. The Games–Howell post-hoc analyses
showed that there was a significant increase in serum
concentrations of oxymorphone and noroxymorphone from
PM to EM, and from PM to URM (all p<0.001). Serum
concentrations of oxymorphone were not statistically signif-
icantly different between EM and URM (p=0.16). Norox-
ymorphone serum concentrations were statistically
significantly lower (p=0.05) in EM compared with URM,
although the result was non-significant after analyses with
covariates (p=0.57); Table 3).
Except for the noroxymorphone serum concentrations,
repeating all analyses with inclusion of covariates
(ANCOVA analyses) gave similar results with respect to
statistical significance (data not shown).
Median oxymorphone/oxycodone ratios were 0.0028,
0.0172 and 0.0244 for the PM, EM and URM respectively
(Fig. 3). There was a significant difference in the metabolic
ratio oxymorphone/oxycodone (F(2,447)=43,16 p<0.000)
among the three genetic groups. The Games–Howell post-
hoc analyses showed that there was a significant increase in
the ratio from PM to EM, and from PM to URM (all p<
0.000). The oxymorphone/oxycodone ratio was also statisti-
cally significant different between EM and URM (p=0.017)
in the ANOVA analysis. However, EM and URM (p=0.121)
were not statistically significant different after inclusion of
the covariates “total daily oxycodone dose”, “use of
CYP3A4 inducer drugs” and “number of co-medications
used by the patient” (data not shown).
Clinical outcomes
Median pain intensity was 4 on the NRS for PM and URM,
and 3 for EM. The difference in pain intensity was non-
significant between the groups (p=0.8).
There were no difference between the groups with regard
to tiredness (p=0.7) and nausea (p=0.6). All three genetic
groups had a median score of 67 and 17 respectively, for the
EORTC QLQ-C30 on tiredness and nausea. There were no
differences in cognitive function among the groups (p=0.8).
PM and URM had a median cognitive function score on the
Mini Mental State of 29, compared with a median of 28 for
EM (Table 4). PM had a median of 33, EM had median of
67 and URM had a median of 50 on the EORTC QLQ-C30
constipation scale (p=0.9). All three genetic groups had a
median score of 2 with regard to depression (data not
shown).
Seven EM and two URM used another regular opioid.
The exclusion of these patients did not change the results
(data not shown).
Discussion
In this cohort of cancer patients it was observed that
oxycodone metabolism, but not oxycodone efficacy, was
influenced by CYP2D6 genotypes.
CYP2D6 activity may have an impact on oxycodone
efficacy because oxymorphone in relevant doses is an
active analgesic [32], and because noroxymorphone may
exhibit an analgesic effect because of its abundance in
serum and its μ-opioid receptor affinity [33].
The PM had lower oxymorphone and noroxymorphone
serum concentrations than the EM and URM, even when
correcting for non-genetic covariates, previously shown to
influence oxycodone pharmacokinetics [34]. However, the
observed difference in noroxymorphone concentrations
between EM and URM was not observed in the analyses
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Fig. 1 Boxandwhiskerplotsofmedianoxycodonetotaldailydose(mg/
24h) with 25th and 75th percentilesamong the three genetic groupspoor
metabolisers (PM, n=27), extensive metabolisers (EM, n=413) and
ultra-rapid metabolisers (URM, n=10). The whiskers represent the 5th
and 95th percentiles
60 Eur J Clin Pharmacol (2012) 68:55–64corrected for covariates, suggesting that the difference in
noroxymorphone between the EM and URM was not
related to CYP2D6 genotypes, but caused by other factors.
Metabolic phenotyping by means of the oxymorphone/
oxycodone ratio clearly separated the PM from the EM and
URM in this sample of unselected, heterogeneous cancer
patients as well. This confirms that CYP2D6 is the dominat-
ing metabolic pathway for the formation of oxymorphone
fromoxycodone.The observationthatmetabolic phenotyping
did not separate EM from URM is also consistent with
previous literature, as EM genotypes may display a metabolic
pattern overlapping with URM genotypes [35].
Significant differences in oxymorphone serum concen-
tration levels for PM compared with EM were also
demonstrated in a fairly large (n=270) study in patients
with post-operative pain [36]. Moreover, Samer et al.’s[ 37]
study in healthy volunteers showed that PM had very low
oxymorphone and noroxymorphone levels compared with
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Fig. 2 Box and whisker plots of
median serum concentrations
(nMolar) of a oxycodone, b
oxymorphone, c noroxycodone
and d noroxymorphone with
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between the three genetic groups
poor metabolisers (PM, n=27),
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Table 3 Post-hoc analyses of variance (ANOVA) between the three
genetic groups: poor metabolisers (PM), extensive metabolisers (EM)
and ultra-rapid metabolisers (URM), for the outcomes that showed an
overall statistical difference (F-test, both p=0.000). The statistically
significantly different groups are shown in italics
Dependent variable
a Groups compared Mean difference between groups (MD) Standard error MD p value* 95% CI for MD
Oxymorphone PM vs EM −0.84 0.15 0.000 −1.21 −0.47
PM vs URM −1.12 0.20 0.000 −1.62 −0.62
EM vs URM –– 0.16 –
Noroxymorphone PM vs EM −1.04 0.18 0.000 −1.50 −0.58
PM vs URM −1.38 0.22 0.000 −1.91 −0.84
EM vs URM −0.34 0.12 0.05** −0.68 −0.0005
*The Games–Howell corrected p values
**No statistical difference (p=0.57) in noroxymorphone between EM and URM in the analyses of covariance (ANCOVA)
a =Log 10 serum concentrations
Eur J Clin Pharmacol (2012) 68:55–64 61EM and URM. Thus, all studies performed in humans
consistently show that CYP2D6 genotypes alter the
pharmacokinetics of oxycodone.
Despite the clear effects of CYP2D6 genotypes on the
pharmacokinetics of oxycodone, no difference was found
between PM, EM and URM in comparing pain intensities,
nausea, tiredness and cognitive function. Thus, this study
suggests that CYP2D6 genotyping and monitoring of
oxycodone serum concentrations and its metabolites do
not have any value in clinical routine practice. This is in
accordance with the clinical study by Zwisler et al. [36],
who were unable to confirm an analgesic effect of
oxymorphone or a difference in the efficacy of oxycodone
between PM and EM, in 270 patients with post-operative
pain treated with oxycodone. Further, no difference was
found in the analgesic effect and adverse events between
EM and URM patients with oxycodone administered for
chronic non-malignant and malignant pain [38].
In contrast, experimental pain studies in healthy volunteers
[39, 40] observed differences among the three CYP2D6
genotypes. In Zwisler et al.’s[ 39] study there was a
difference between EM and PM with regard to the analgesic
effect of oxycodone on pain detection threshold, tolerance
threshold and the cold pressor test. Samer et al. [40]s h o w e d
differences in pain tolerance- and subjective pain thresholds
(URM>EM>PM) and differences between URM and EM in
psychomotor tests (p<0.05). However, an important shared
limitation is that these two studies were single-dose oxy-
codone studies performed in healthy volunteers.
Our study suggests that oxymorphone and noroxymor-
phone do not contribute to the efficacy of oxycodone in a
clinical setting with cancer patients. The reason for the lack
of the pharmacodynamic effect of the potent compound
oxymorphone could potentially be the very low level of this
metabolite relative to oxycodone [33]. The median oxy-
morphone serum concentrations in this study were 0.2, 1.5
and 3.1% of the median oxycodone serum concentrations in
the PM, EM and URM respectively.
Median noroxymorphone serum concentrations consti-
tute 2.3, 16.8 and 46% of the median oxycodone serum
concentrations in the PM, EM and URM respectively. A
difference in pain intensity or adverse events between PM
and URM would be expected if noroxymorphone was an
active metabolite, maybe also between PM and EM,
because of the relatively large difference between the
genotypes of noroxymorphone concentrations relative to
oxycodone. This was not the case; there was no difference
among PM, EM and URM with regard to effect or adverse
events; thus, it seems unlikely that noroxymorphone is an
important active metabolite of oxycodone.
The usage of CYP2D6 inhibitor medication was included
in the covariate analyses of the efficacy of oxycodone. No
association was found, which suggests that CYP2D6 inhibi-
tion does not affect the efficacy of oxycodone. The prevalence
ofco-medicationwitha CYP2D6inhibitorwasonlyabout8%
and, therefore, a relevant difference could be undisclosed.
However, this lack of impact from the use of CYP2D6
inhibitors is in accordance with other studies where inhibition
of the CYP2D6 metabolic pathway with paroxetine or
quinidine did not influence the efficacy of oxycodone in
healthyvolunteers[40–43], or patients with chronic pain [38].
We recognise some limitations to this study. First, is the
lack of observations before and after interventions. Therefore,
conclusions about causal relationships should be applied with
cautionowingtoitscross-sectionaldesign.Second,withmore
than 80 known allelic variants of the CYP2D6 gene, it was
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Fig. 3 Box and whisker plots of the median ratio of oxymorphone/
oxycodonewith25thand75thpercentilesamongthethreegeneticgroups
poormetabolisers(PM,n=27), extensive metabolisers (EM, n=413)and
ultra-rapid metabolisers (URM, n=10). The whiskers represent the 5th
and 95th percentiles
Table 4 Patient ratings of symptoms for the three genetic groups
given as medians (minimum to maximum). Pain intensity from the
Brief Pain Inventory, the tiredness and nausea score from the EORTC-
QLQ-C30 and cognitive function from the Mini Mental State examine
score. No statistically significant differences were found (one-way
ANOVA and ordinal logistic regression analyses)
Poor metabolisers Extensive metabolisers Ultra-rapid metabolisers
Pain intensity 4 (0–6) 3 (0–10) 4 (0–6)
Tiredness 67 (0–100) 67 (0–100) 67 (0–100)
Nausea 17 (0–83.33) 17 (0–100) 17 (0–50)
Cognitive function 29 (20–30) 28 (14–30) 29 (20–30)
62 Eur J Clin Pharmacol (2012) 68:55–64necessary to make a selection of which to study. We chose to
use a panel of variant used by the Department of Pathology
and Medical Genetics, St. Olav University Hospital, to
determine PM, EM and URM. They have chosen variants
that show clinically significant alteration of enzyme activity,
omitting those that have no verified or insignificant effect on
drug metabolism in vivo or those that are extremely rare. We
chose to analyse for these routine allelic variants as the aim
was to make judgements closely related to everyday clinical
and laboratory practice. Finally, as in all clinical cancer pain
cohorts the patients included in this study are heterogeneic
with regard to characteristics that may affect pain intensity
and other symptoms. In studies in healthy volunteers pain
mechanisms are equal for all participants, and the partic-
ipants are more homogeneous. However, experimental pain
has little relevance in clinical practice, while our results
reflect the clinical setting. Thus, in this cohort with chronic
cancer pain, oxymorphone does not seem to contribute to the
analgesic effect of oxycodone.
Conclusion
Patients categorised as PMs of oxycodone have statistically
significantly lower serum concentrations of oxymorphone
and noroxymorphone and oxymorphone/oxycodone ratios
than EM and URM. However, no difference was found
among PM, EM and URM when comparisons of their pain
intensities, nausea, tiredness and cognitive function were
made. The CYP2D6 genotype does not reflect oxycodone
requirements and it is not associated with common adverse
effects in this study of patients with cancer pain.
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